See referenced original article on pages 2728–36, this issue.
CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia
Version of Record online: 30 APR 2013
© 2013 American Cancer Society
Volume 119, Issue 15, pages 2671–2674, 1 August 2013
How to Cite
Hoelzer, D. (2013), CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia. Cancer, 119: 2671–2674. doi: 10.1002/cncr.28135
- Issue online: 18 JUL 2013
- Version of Record online: 30 APR 2013
- Manuscript Accepted: 3 APR 2013
- Manuscript Received: 2 APR 2013
Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.